Biotech / Finance

Analyst on the hospital stocks' three-day rally as GOP health-care bill gets postponed

Mar 24 4:33pm Health Care
Hospital stocks continue their three-day rally as the GOP health-care bill got postponed for the second time on Friday.
Read More

Obamacare replacement vote yanked in House as GOP fails to win support

Mar 24 4:23pm Health Care
For the second time, GOP leaders postponed a scheduled vote amid objections from conservatives and moderates.
Read More

Paul Ryan says House will 'proceed' with tax reform despite health-care 'setback'

Mar 24 4:14pm Health Care
"We came really close today, but we came up short," Ryan said.
Read More

What do Trump and Ryan really think about Obamacare?

Mar 24 4:07pm Health Care
Here's a running list of things President Trump and Republican Speaker Paul Ryan have said about Obamacare.
Read More

Simple math shows why passing the health bill was very important for passing tax reform

Mar 24 3:55pm Health Care
Failing to replace Obamacare creates a budget crunch that could make tax reform a whole lot harder to achieve.
Read More

Watch: House Speaker Paul Ryan talks after GOP yanks Obamacare replacement

Mar 24 3:48pm Health Care
The GOP failed to rally the support needed to pass the bill, facing pressure from both its conservative and moderate wings.
Read More

Do Analysts See A Path Forward For Ophthotech's Fovista?

Mar 24 3:35pm Biotech
After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing results from two Phase 3 studies in December, Leerink analysts Joseph Schwartz and Dae Gon Ha said in a note. The studies compared the effectiveness of the drugs Fovista and Lucentis together vs. Lucentis monotherapy. A recent Ophthotech earnings call provided opportunity for the Leerink analysts to learn more about the strategic review plan the company announced earlier this month. The Way Forward Ophthotech is proceeding with a Phase 3 clinical trial of Fovista, administered in combination with Eylea or Avastin. This route could generate a new ...Full story available on Benzinga.com...
Read More

Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive

Mar 24 3:18pm FDA
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is on the verge of becoming a commercial biotech company, as its PDUFA date for Ingrezza in tardive dyskynesia (TD) approaches. The FDA is expected to announce a decision in early April. Consequently, Neurocrine’s management team has shifted its focus to the drug’s commercialization and sales potential, Barclays analysts Geoff Meacham, Ph.D., and Paul Choi revealed in a report issued Friday. Given the relevance of Ingrezza in Barclays’ thesis on the company, the analysts decided to reach out to specialist physicians, seeking to arrive at a better assessment of the opportunity the ...Full story available on Benzinga.com...
Read More

Americans ought to be disgusted with Congress, House Democratic Whip says

Mar 24 3:11pm Health Care
House Democratic Whip Steny Hoyer told CNBC on Friday he doesn't blame Americans who may have lost faith in Congress, because he feels their pain.
Read More

Trump has 'left everything on the field' for health-care bill, Spicer says

Mar 24 1:57pm Health Care
The White House spokesman says the House is scheduled to vote on the GOP health bill at 3:30 p.m. ET.
Read More

'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market

Mar 24 1:50pm FDA
The journey is just beginning for Glenn King, a researcher whose team found that the world’s most poisonous spider could provide fast treatment for stroke victims and stop their brain cells from burning out. The initial findings were presented this week in the journal Proceedings of the National Academy of Sciences. Media coverage has been huge in Britain and King’s homeland, Australia, while U.S. attention has been scant. To investors, this is biotech at its most basic; the discovery process, something happening in a distant laboratory. The years-long route from lab rats to FDA drug approval will be painstaking, exacting, and not necessarily successful. “We’ve been down this road dozens and dozens of times,” Dr. Larry Goldstein, professor and chairman of the Department of Neurology at the University of Kentucky and past chair of The Stroke Council of the American Heart Association, told Benzinga. “It is certainly a novel approach and looks interesting,” he said of King’s research. “Whether it pans out is complete conjecture.” A Deadly Creature’s Hidden Gift King, a scientist at the University of Queensland Institute for Molecular Bioscience, experiments with the venom of scorpions, centipedes and spiders to find treatments for a variety of diseases, from chronic pain to erectile dysfunction. His lab is filled with 50 types of venom and the living ...Full story available on Benzinga.com...
Read More

Paul Ryan reportedly tells Trump the GOP lacks votes to pass Obamacare replacement

Mar 24 1:41pm Health Care
Republicans are trying to rally support for their Obamacare replacement bill ahead of a House vote.
Read More

Trump shrugs, says 'we'll have to see' when asked what happens if his Obamacare replacement fails

Mar 24 11:58am Health Care
Trump's American Health Care Act faces opposition from conservative and moderate members of the Republican caucus.
Read More

How The American Health Care Act Could Affect Digital Health

Mar 24 10:55am Science Business
Although the future is uncertain, it's clear that industry experts all agree on one thing: digital innovation in healthcare will have an even greater impact in light of the changes ahead.
Read More

Here Are The 4 Commercial Launches In 2017 That Earned Tesaro A Buy Rating At Argus

Mar 24 10:49am Biotech
TESARO Inc (NASDAQ: TSRO) has strong prospects in immuno-oncology, as it prepares for four commercial launches in 2017 and plans to initiate pivotal studies for several products, Argus’s Stephen Biggar said in a report. He initiated coverage of the company with a Buy rating and a price target of $210. Tesaro reported a net loss for fourth-quarter 2016 of $2.60 per share, versus $1.89 in Q4 of 2015. Revenue came in at $4.2 million, compared to $0.2 million in Q4 2015. Product Pipeline Tesaro has planned new product launches in the US and Europe. “We expect continued ...Full story available on Benzinga.com...
Read More

Freedom Caucus holdout blasts Obamacare replacement bill as largest welfare program in GOP history

Mar 24 9:59am Health Care
Rep. Mo Brooks tells CNBC the House Obamacare replacement plan is the worst bill he's seen in 30 years of public service.
Read More

Not statistically significant but clinically meaningful: A researcher calls BS on cancer drug spin

Mar 24 9:49am Health News Review
An egregious example of pharma spin was highlighted by Dr. Vinay Prasad, an oncologist at Oregon Health Sciences University, this week on Twitter. He pointed to a Novartis promotional website for the immunosuppressant drug everolimus (brand name Afinitor) that’s used to treat kidney and other cancers. His annotation of a graphic on the site called […]...
Read More

Judge dismisses two Express Scripts claims in Anthem drug pricing lawsuit

Mar 24 9:27am Health Care
Judge Edgardo Ramos in Manhattan dismissed Express Scripts' claim that Anthem breached an implied covenant of good faith and fair dealing.
Read More

Trump presses Freedom Caucus on health care: A no vote helps Planned Parenthood

Mar 24 9:17am Health Care
Trump warns the Freedom Caucus that federal funding will still go to Planned Parenthood if the status quo is maintained.
Read More

Believe Trump pass GOP health bill or Obamacare stays, warns White House budget director Mulvaney

Mar 24 9:05am Health Care
White House budget director Mick Mulvaney also tells CNBC he's not sure the administration has enough votes for passage.
Read More

These are the lawmakers deciding on maternity coverage repeal

Mar 24 8:26am Health Care
You may notice a certain group of people missing from decisions on AHCA's repeal of "essential benefits," Vox reports.
Read More

Freedom Caucus member: Obamacare replacement bill is largest welfare program in GOP history

Mar 24 8:25am Health Care
Rep. Mo Brooks tells CNBC the House Obamacare replacement plan is the worst bill he's seen in 30 years of public service.
Read More

European Medicines Agencys CHMP Recommends Approval of Mercks KEYTRUDA (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Mar 24 8:13am Prescription Medicine News
Dateline City: KENILWORTH, N.J. Recommendation Is for Adult Patients Who Have Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who Are Transplant-Ineligible and Have Failed BV KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligib Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more...
Read More

Don't expect a Seinfeld yada-yada-it-becomes-law scenario if GOP health bill advances, AEI warns

Mar 24 8:04am Health Care
The imperiled GOP Obamacare replacement bill would still face a difficult road to becoming law, an AEI analyst says.
Read More

Five Questions to Ask When Selling Your Pharmacy

Mar 24 7:30am Drug Channels
Today’s guest post comes from Christian Herrington, Corporate Vice President Pharmacy Strategies for H.D. Smith.Christian addresses five frequently asked questions for pharmacy owners who are considering selling their pharmacy. To help independent pharmacies both navigate and direct the sales process, H. D. Smith created VentureRx.VentureRx fully supports the sale, purchase, start-up and transition strategies of pharmacies. Click here for a free, no-obligations needs assessment from VentureRx.Read on for Christian’s insights.To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (paula@drugchannelsinstitute.com).Read more »Copyright © 2006-2017 Pembroke Consulting, Inc. and Copyright © 2006-2017 Drug Channels. This Feed is for personal non-commercial use only.         ...
Read More

Here are the stocks that win if the Trump-Ryan health-care bill passes, says top analyst

Mar 24 7:20am Health Care
UnitedHealth Group, Anthem and Humana are among the big winners of a key Republican-led health-care bill, Gupte says.
Read More

Big data approach to predict protein structure

Mar 24 7:14am Nanowerk Biotech News
To develop methods to repair malfunctioning proteins, their structure has to be known. Using a big data approach, researchers have now developed a method to predict protein structures.            ...
Read More

Biotech Stocks Facing FDA Decision In April

Mar 24 6:33am RTT - Biotech
The month of March saw many firsts in terms of new drug approvals. Now, let's take a look at the biotech stocks awaiting FDA decision in April.
Read More

Obamacare supporters rally against congressional repeal efforts

Mar 24 6:27am Health Care
Obamacare supporters staged rallies across the country denouncing efforts by President Donald Trump and GOP congressional leaders to repeal the law.
Read More

Health-care vote showdown: Republicans look to go big or go home

Mar 24 5:55am Health Care
Another day, another chance to pass the Republican health care plan.
Read More

Amgens Amgevita secures approval in Europe for certain inflammatory diseases

Mar 24 5:23am PBR - News
Amgen’s Amgevita (biosimilar adalimumab) has been granted the marketing authorization by the European Commission (EC) in all available indications.
Read More

BioLineRx acquires UK cancer immunotherapeutics company Agalimmune

Mar 24 5:22am PBR - News
Clinical-stage biopharmaceutical firm BioLineRx has purchased Agalimmune, a private UK-based company with an anti-cancer immunotherapy platform.
Read More

Eurofins pumping $5m into a UK biopharmaceutical testing site

Mar 24 5:15am in-PharmaTechnologist RSS
Eurofins will expand its UK biopharmaceutical testing offering through a £4m ($5m) facility in Livingston, Scotland.
Read More

Merck, Pfizer get FDA nod for Bavencio to treat metastatic Merkel cell carcinoma

Mar 24 2:29am PBR - News
Merck’s EMD Serono and Pfizer have secured approval from the US Food and Drug Administration (FDA) for Bavencio (avelumab) injection 20 mg/mL to treat metastatic Merkel cell carcinoma (mMCC).
Read More

FDA Approves First-ever Merkel Cell Carcinoma Drug, HTGM Riding High, FLXN Soars

Mar 24 1:11am RTT - Biotech
The FDA has approved Merck KGaA and Pfizer Inc.'s (PFE) BAVENCIO Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, a rare and aggressive skin cancer.
Read More

Week 27: You are my son-shine

Mar 24 12:00am Knocked Up – Pregnancy & Newborn Magazine
I have a wonderful 9-year-old daughter and two delightful sons, ages 3 and 6. It would be easy to get excited about adding another girl to the mix, but you know, having a herd of boys has its perks, too. … Continue reading → The post Week 27: You are my son-shine appeared first on Pregnancy & Newborn Magazine.
Read More

Trump demands Friday health-care vote and Ryan says 'we're proceeding'

Mar 23 8:45pm Health Care
Republicans struggled to rally enough support for the bill to repeal and replace parts of the Affordable Care Act, prompting President Donald Trump to seek a vote on Friday.
Read More

Despite Recent Layoffs, Eli Lilly to Invest $850 Million in U.S. Operations

Mar 23 8:00pm BioSpace.com Featured News
  Life Sciences Jobs   ...
Read More

Old Blood Can Be Made Young Again And It Might Fight Ageing, University of Ulm Reveals

Mar 23 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

The Science Of Sex's 'Afterglow', Study Reveals

Mar 23 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

This Colorado Pharma May Not Have Enough Cash to Last 2017

Mar 23 8:00pm BioSpace.com Featured News
  Life Sciences Jobs   ...
Read More

Why Merck & Co.'s $95 Million Bet on in 2015 Did Not Pay Off

Mar 23 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

Trump said to be done negotiating, demands Friday health-care vote

Mar 23 7:55pm Health Care
Republicans struggled to rally enough support for the bill to repeal and replace parts of the Affordable Care Act, prompting President Donald Trump to seek a vote on Friday.
Read More

New CBO estimate of Obamacare replacement shows no further drop in insured, but 'smaller savings'

Mar 23 5:38pm Health Care
The new projections of budget effects came after a postponement of a planned vote on the Republican bill.
Read More

Hamilton fans troll Trump on Twitter after Obamacare replacement vote postponed

Mar 23 5:04pm Health Care
Hamilton fans took to Twitter Thursday to troll Donald Trump after the vote on the Republican's replacement plan for Obamacare was postponed.
Read More

Head of House Freedom Caucus says GOP needs 30 to 40 votes more to pass Obamacare replacement

Mar 23 4:52pm Health Care
The House of Representatives postponed a planned vote on the replacement bill Thursday.
Read More

Arbutus Announces Appointment of Daniel Burgess to Board of Directors

Mar 23 4:30pm Biotech
VANCOUVER, B.C. and DOYLESTOWN, Pa., March 23, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company has appointed Daniel Burgess to the Board of Directors and Audit Committee effective immediately. Mr. Burgess has more than 25 years of executive level operating experience in biotech companies, including substantial experience in the anti-infective field.  He is currently a Venture Partner at SV Life Sciences, is Chairman of the Board of Nabriva Therapeutics (NASDAQ:NBRV) and is on the board ...Full story available on Benzinga.com...
Read More

GOP health-care bill a 'big step backward,' Molina Healthcare CEO says

Mar 23 4:22pm Health Care
As leaders tried to muster support for the GOP health-care bill, one insurance executive said the measure is a bad idea.
Read More

House delays Obamacare replacement vote as it struggles to muster votes: Sources

Mar 23 4:01pm Health Care
Republicans struggled to rally enough support for the bill to repeal and replace parts of the Affordable Care Act.
Read More

Expect Stemline To Generate Acquisition Interest As SL-401 Approval Decision Nears

Mar 23 3:20pm Biotech
Stemline Therapeutics Inc (NASDAQ: STML) shares were sliding Thursday after the company announced the completion of enrollment of Stage 3 in the SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and reviewed key milestones for the SL-401 program over the coming year. BPDCN is acute myeloid leukemia, which is a type of cancer of blood and bone marrow with excess immature WBC. In a quick note. Wedbush delved on the company's announcement and offered its take on the timeline for approval and sales estimate. Additionally, the firm broached the possibility of the company being a takeover target. Enrollment Details Wedbush noted that the company reported enrollment of 13 first-line patients in the third cohort of a mid-stage study of SL-401, following up on the four to six patients enrolled in the third cohort during the first week of January. The firm termed the speed of enrollment as impressive, given that ...Full story available on Benzinga.com...
Read More

White House's Spicer says there's no backup plan for health-care bill because it will pass

Mar 23 2:45pm Health Care
"No. It's gonna pass, so that's it," Spicer said in his daily press briefing.
Read More

Freedom Caucus says 'not enough votes' after White House's 'final offer' on Obamacare replacement

Mar 23 2:13pm Health Care
The lack of an agreement throws more doubt on a planned Thursday night vote on the crucial legislation.
Read More

Americans strongly oppose Republican Obamacare replacement bill ahead of big vote

Mar 23 1:19pm Health Care
The House of Representative is scheduled to vote on the GOP replacement plan for Obamacare on Thursday.
Read More

500,000 jobs added to health-care sector under Obamacare, Goldman Sachs estimates

Mar 23 12:24pm Health Care
The analysis comes as the House of Representatives is poised to vote on a bill to replace key parts of Obamacare.
Read More

On health reform, Democrats and Republicans dont speak the same language

Mar 23 11:55am Health Care
An analysis of 575 press releases from party officials share vastly different messages, ProPublica reports.
Read More

Toxic cocktail of factors show why the white middle class is dying faster

Mar 23 11:43am Health Care
New research illuminates the complicated collapse of middle-aged white Americans, Vox reports.
Read More

Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook

Mar 23 10:53am Biotech
Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s refinancing announcement on Tuesday shouldn't be celebrated by investors, at least according to Gadfly's Max Nisen. Nisen noted Valeant's financial wizardry doesn't address Valeant's long-term $30 billion debt load although it may ease short-term obligations. Specifically, the company issued new debt, which will be due in 2022 and 2024. However, the proceeds will be used to satisfy debt that is maturing in the near term. Nisen suggested the new debt raise was necessary as Valeant has little realistic chance of growth. In fact, the company is playing a game of music ...Full story available on Benzinga.com...
Read More